Top Medical News
12 hours ago
The monoclonal antibody abrilumab is effective for treating moderate-to-severe ulcerative colitis, promoting remission, clinical response and mucosal healing, a recent study has found.
Roshini Claire Anthony, Yesterday

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Yesterday
Sorafenib, in combination with conventional transarterial chemoembolization (cTACE), does not significantly improve overall survival (OS) in hepatocellular carcinoma (HCC) patients, relative to sorafenib alone, a recent study has found.
Rachel Soon, 2 days ago

At the recent forum “Improving Access to Affordable Cancer Treatments in Malaysia”, the issue of treatment costs was discussed by panellists from the Ministry of Health (MOH) and pharmaceutical industry representatives.

Roshini Claire Anthony, 2 days ago

Long-term results of the POET* trial have suggested that patients with left-sided infective endocarditis (IE) could safely switch from conventional intravenous (IV) antibiotics to oral antibiotics, with oral antibiotics associated with a reduced mortality risk.

Audrey Abella, 2 days ago
Icosapent ethyl – a prescription and highly purified version of the omega-3 fatty acid, eicosapentaenoic acid (EPA) – takes the spotlight in REDUCE-IT* as it markedly reduced the rate of total ischaemic events in individuals with high cardiovascular (CV) risk**.
Jackey Suen, 2 days ago

Sarcopenia, a condition previously underrecognized in clinical practice, has now become a focus of intense research.

Special Reports
Dr. Jeffrey Ross, Dr. Rohit Lal, Prof. Alwin Krämer, Dr. Rebecca Dent, Prof. Rafal Dziadziuszko, 24 Jan 2019
Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.
Dr. Choo Gim Hooi, Assoc Prof. Pattarapong Makarawate, Dr. Krisada Sastravaha, 17 Dec 2018
Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa®).
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

27 Sep 2018
PRALUENT – alirocumab 75 mg/mL and 150 mg/mL soln for inj - sanofi-aventis
27 Sep 2018
VICTOZA – Liraglutide 6 mg/mL soln for inj - Novo Nordisk
Conference Reports
Roshini Claire Anthony, 21 Mar 2019

Long-term results of the POET* trial have suggested that patients with left-sided infective endocarditis (IE) could safely switch from conventional intravenous (IV) antibiotics to oral antibiotics, with oral antibiotics associated with a reduced mortality risk.

Audrey Abella, 21 Mar 2019
Icosapent ethyl – a prescription and highly purified version of the omega-3 fatty acid, eicosapentaenoic acid (EPA) – takes the spotlight in REDUCE-IT* as it markedly reduced the rate of total ischaemic events in individuals with high cardiovascular (CV) risk**.
Roshini Claire Anthony, 20 Mar 2019

The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).

Audrey Abella, 20 Mar 2019
The humanized immunoglobulin G1 monoclonal antibody risankizumab provided durable clinical efficacy compared with ustekinumab in individuals with moderate-to-severe plaque psoriasis, according to integrated analyses of UltIMMa-1 and 2* presented at AAD 2019.
Audrey Abella, 19 Mar 2019
Long-term use of the humanized immunoglobulin G1K monoclonal antibody tildrakizumab generated durable responses in adult patients with moderate-to-severe chronic plaque psoriasis*, according to the results of the 3-year extension phases of reSURFACE 1** and 2*** presented at AAD 2019.

Audrey Abella, 14 Mar 2019
The novel Janus kinase (JAK) inhibitor delgocitinib exhibited favourable efficacy and safety for moderate-to-severe atopic dermatitis (AD), according to a phase III study presented at AAD 2019.
Elvira Manzano, 04 Mar 2019
The perception that the more aggressive glucose control is the better the patient will be doesn’t hold true in the multicentre SHINE* trial. Intensive glucose control at a target of 80–130 mg/dL with intravenous (IV) insulin did not improve outcomes in patients with ischaemic stroke. Instead, it carried an increased risk of severe hypoglycaemia.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download